Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
S&S Healthcare Holding's earnings before interest and taxes (EBIT) for the
three
months ended in Dec. 2025 was NT$-10.4 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-47.4 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
S&S Healthcare Holding's annualizedROC % for the quarter that ended in Dec. 2025 was -22.51%.
S&S Healthcare Holding's annualizedROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -39.45%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
S&S Healthcare Holding's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -5.33%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, S&S Healthcare Holding's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
S&S Healthcare Holding EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, S&S Healthcare Holding's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where S&S Healthcare Holding's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-47.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
S&S Healthcare Holding (ROCO:4198) has a EBIT of NT$-47.4 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on S&S Healthcare Holding.
Is S&S Healthcare Holding's EBIT too high?
S&S Healthcare Holding's current EBIT is NT$-47.4 Mil. Overall, S&S Healthcare Holding has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does S&S Healthcare Holding's EBIT compare to ABT and SYK?
S&S Healthcare Holding's EBIT of NT$-47.4 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on S&S Healthcare Holding. S&S Healthcare Holding's current EBIT is NT$-47.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is S&S Healthcare Holding stock overvalued right now?
Based on GuruFocus' analysis, S&S Healthcare Holding (ROCO:4198) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$23.67, compared to a current price of NT$38.05 — trading 60.8% above its estimated fair value. The current EBIT is NT$-47.4 Mil. S&S Healthcare Holding's overall GF Score™ is 54/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For S&S Healthcare Holding (ROCO:4198), the current EBIT is NT$-47.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is S&S Healthcare Holding (ROCO:4198) Overvalued in 2026?
Based on GuruFocus' analysis, S&S Healthcare Holding stock appears to be overvalued.
The current stock price of NT$38.05 is trading 60.8% above its estimated GF Value™ of NT$23.67.
GuruFocus considers S&S Healthcare Holding to be Significantly Overvalued.
Key valuation signals for ROCO:4198:
EBIT: NT$-47.4 Mil
GF Value™: NT$23.67 vs. price of NT$38.05 (60.8% above fair value)
No single metric tells the full story. See the ROCO:4198 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
S&S Healthcare Holding Ltd, formerly Swissray Global Healthcare Holding Ltd is involved in providing DR systems designed for any application in general radiography. The product divisions of the company cover Swissray DDR systems, Novadaq, and EZ2GO. The main business projects of the company and its subsidiaries are the research and development, manufacturing, sales, and maintenance services of high-end medical equipment and the manufacturing and sales of basic medical equipment.
54GF Score
Get the complete analysis for ROCO:4198
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4198 has been successfully added to your 
